Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minocycline inhibits cell death and decreases mutant Huntingtin aggregation by targeting Apaf-1.

Human molecular genetics - 15 Sept 2011

Sancho Mónica, Herrera Andrés E, Gortat Anna, Carbajo Rodrigo J, Pineda-Lucena Antonio, Orzáez Mar, Pérez-Payá Enrique

Abstract excerpt

Minocycline (7-dimethylamino-6-dimethyl-6-deoxytetracycline) is a second-generation tetracycline that can cross the blood-brain barrier and has anti-inflammatory and neuroprotective effects. The potential of minocycline as a drug for treating Huntington's disease has been studied; however, the molecular mechanism underlying the neuroprotective properties of minocycline remains elusive. In this study, we tested...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Apoptotic Protease-Activating Factor 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Death

Share to Down-Regulation

Share to Huntingtin Protein

Share to Huntington Disease

Share to Minocycline

Share to Nerve Tissue Proteins

Source

Identifiers

PMID: 21659333
DOI: 10.1093/hmg/ddr271

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minocycline inhibits cell death and decreases mutant Huntingtin aggregation by targeting Apaf-1.PMID 21659333Read ↗

Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfoldingSemantic proximity Read ↗

Minocycline for Huntington’s disease: An open label studySemantic proximity Read ↗

Molecular mechanisms of 10-Butyl Ether Minocycline (BEM), a novel non-antibiotic tetracycline, as a potential treatment for inflammatory and neuroimmune-related disordersSemantic proximity Read ↗

Doxycycline: An essential tool for Alzheimer’s diseaseSemantic proximity Read ↗

Minocycline Attenuates Neuronal Cell Death and Improves Cognitive Impairment in Alzheimer's Disease ModelsSemantic proximity Read ↗

Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cellsSemantic proximity Read ↗

Minocycline, a possible neuroprotective agent in Leber's hereditary optic neuropathy (LHON): studies of cybrid cells bearing 11,778 mutation.Semantic proximity Read ↗

Normal aging hyperactivates innate immunity and reduces the medical efficacy of minocycline in brain injurySemantic proximity Read ↗

Minocycline in Acute Traumatic Spinal Cord Injury: A Systematic Review and Exploratory Meta-Analysis of Preclinical and Clinical EvidenceSemantic proximity Read ↗

Minocycline Promotes Functional Recovery in Ischemic Stroke by Modulating Microglia Polarization Through STAT1/STAT6 PathwaysSemantic proximity Read ↗

A Case of COVID-19 Successfully Treated with Minocycline and Saiko-Keishi-ToSemantic proximity Read ↗

Minocycline in phenotypic models of Huntington's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.